Low-Acuity Patients Delay High-Acuity Patients in EDs
Abstract
This paper provides evidence that the arrival of an additional low-acuity patient substantially increases the wait time to start of treatment for high-acuity patients, contradicting the long-standing prior conclusion in the medical literature that the effect is "negligible." Whereas the medical literature underestimates the effect by neglecting how delay propagates in a queuing system, this paper develops and validates a new estimation method based on queuing theory, machine learning and causal inference. Wait time information displayed to low-acuity patients provides a quasi-randomized instrumental variable. This paper shows that a low-acuity patient increases wait times for high-acuity patients through: pre-triage delay; delay of lab tests ordered for high-acuity patients; and transition delay when an ED interrupts treatment of a low-acuity patient in order to treat a high-acuity patient. Hence high-acuity patients' wait times could be reduced by: reducing the standard deviation or mean of those transition delays, particularly in bed-changeover; providing vertical or "fast track" treatment for more low-acuity patients, especially ESI 3 patients; standardizing providers' test-ordering for low-acuity patients; and designing wait time information systems to divert (especially when the ED is highly congested) low-acuity patients that do not need ED treatment.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.